Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use CUTAQUIG safely and effectively. See full prescribing information for CUTAQUIG. CUTAQUIG® (Immune Globulin Subcutaneous (Human) - hipp), 16.5% solution Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-other
CUTAQUIG (Immune Globulin Subcutaneous (Human) - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
- generic_name
- immunoglobulin g
- product_names
- immunoglobulin G
- ndc
- 0069-1061, 0069-1061-01, 0069-1061-02, 0069-1802, 0069-1802-01, 0069-1802-02, 0069-1476, 0069-1476-01, 0069-1476-02, 0069-1960, 0069-1960-01, 0069-1960-02, 0069-1509, 0069-1509-01, 0069-1509-02, 0069-1965, 0069-1965-01, 0069-1965-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en